OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

A phase 3 trial of Tislelizumab, Cisplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by BeiGene, active and no longer recruiting.